Next Article in Journal
Immune Checkpoint Inhibitors in Genitourinary Malignancies
Previous Article in Journal
Use of Immuno-Oncology in Melanoma
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers

Medical Oncology, BC Cancer, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s2), 59-68; https://doi.org/10.3747/co.27.5095
Submission received: 2 January 2020 / Revised: 12 February 2020 / Accepted: 10 March 2020 / Published: 1 April 2020

Abstract

Immunotherapy has been described as the “fourth pillar” of oncology treatment, in conjunction with surgery, chemotherapy, and radiotherapy. However, the role of immunotherapy in gastrointestinal tumours is still evolving. Data for checkpoint inhibition in esophagogastric, hepatocellular, colorectal, and anal squamous cell carcinomas are expanding. In phase iii trials in the second-line setting, PD-1 inhibitors have demonstrated positive results for the subset of esophageal cancers that are positive for PD-L1 at a combined positive score of 10 or more. Based on results of phase ii trials, PD-1 inhibitors were approved in North America for use in PD-L1–positive chemorefractory gastric cancers, in hepatocellular carcinoma after sorafenib exposure, and in treatment-refractory deficient mismatch repair (dmmr) or high microsatellite instability (msi-h) tumours, regardless of tissue site. Combination use of PD-1 and ctla-4 inhibitors has been approved by the U.S. Food and Drug Administration for chemorefractory dmmr or msi-h colorectal cancer. Responses to checkpoint inhibition are durable, particularly in the dmmr or msi-h colorectal cancer cohort. As trials of combination immunotherapy, immunotherapy in combination with other systemic therapies, and immunotherapy in combination with other treatment modalities move forward in multiple tumour sites, cautious optimism is called for. The treatment landscape is continually changing, and expanded indications are likely to be just around the corner.
Keywords: gastrointestinal neoplasms; esophageal neoplasms; stomach neoplasms; hepatocellular cancer; colorectal neoplasms; monoclonal antibodies; immunologic antineoplastic agents; microsatellite instability gastrointestinal neoplasms; esophageal neoplasms; stomach neoplasms; hepatocellular cancer; colorectal neoplasms; monoclonal antibodies; immunologic antineoplastic agents; microsatellite instability

Share and Cite

MDPI and ACS Style

Mendis, S.; Gill, S. Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers. Curr. Oncol. 2020, 27, 59-68. https://doi.org/10.3747/co.27.5095

AMA Style

Mendis S, Gill S. Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers. Current Oncology. 2020; 27(s2):59-68. https://doi.org/10.3747/co.27.5095

Chicago/Turabian Style

Mendis, S., and S. Gill. 2020. "Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers" Current Oncology 27, no. s2: 59-68. https://doi.org/10.3747/co.27.5095

APA Style

Mendis, S., & Gill, S. (2020). Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers. Current Oncology, 27(s2), 59-68. https://doi.org/10.3747/co.27.5095

Article Metrics

Back to TopTop